Derek Tang

Bristol-Myers Squibb (Germany) — Germany

Medicine · Health Sciences

22h-index1.3kcitations124works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myeloproliferative Neoplasms: Diagnosis and Treatment(35), Acute Myeloid Leukemia Research(33), Hemoglobinopathies and Related Disorders(29), Advanced Breast Cancer Therapies(22), Chronic Myeloid Leukemia Treatments(18)

Publications123 total

Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US
Blood·2025Open Access
Real-world treatment patterns and outcomes of first-line luspatercept in patients with myelodysplastic syndromes in the United States
Blood·2025Open Access
Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review
Journal of Medical Economics·2025Open Access
MPN-678: Anemia Burden in Patients With Myelofibrosis Treated With a JAK Inhibitor: Data From the Optum Market Clarity Database
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MPN-678 Anemia Burden in Patients With Myelofibrosis Treated With a JAK Inhibitor: Data From the Optum Market Clarity Database
Clinical Lymphoma Myeloma & Leukemia·2025
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study – SIMPLICITY
Leukemia & lymphoma/Leukemia and lymphoma·2025· 1 cited
Real-world (RW) outcomes of patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) receiving first-line (1L) luspatercept (LUSPA) or 1L erythropoiesis-stimulating agents (ESA) in the US.
Journal of Clinical Oncology·2025
Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study
Journal of Medical Economics·2025Open Access
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment
PharmacoEconomics·2024· 1 citedOpen Access
Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison
Future Oncology·2024Open Access
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study
Leukemia Research·2024· 8 citedOpen Access
Burden and Clinical Outcomes in Patients (pts) with Myelofibrosis (MF) and Anemia Treated with Ruxolitinib (RUX): Data from the Veterans Affairs Corporate Data Warehouse (VACDW)
Blood·2024
MDS-276 Management of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoiesis-Stimulating Agent (ESA) Treatment
Clinical Lymphoma Myeloma & Leukemia·2024
Management of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoiesis-Stimulating Agent (ESA) Treatment
Clinical Lymphoma Myeloma & Leukemia·2024
Anemia Burden in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): Data From the Veterans Affairs Corporate Data Warehouse (VACDW)
Clinical Lymphoma Myeloma & Leukemia·2024
MDS-059 Real-World Impact of Luspatercept Versus Erythropoiesis-Stimulating Agents (ESAs) on the Healthcare Resource Utilization (HRU) of Patients With Myelodysplastic Syndromes (MDS) in the United States (US)
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
Real-World Impact of Luspatercept Versus Erythropoiesis-Stimulating Agents (ESAs) on the Healthcare Resource Utilization (HRU) of Patients With Myelodysplastic Syndromes (MDS) in the United States (US)
Clinical Lymphoma Myeloma & Leukemia·2024
MPN-203 Anemia Burden in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): Data From the Veterans Affairs Corporate Data Warehouse (VACDW)
Clinical Lymphoma Myeloma & Leukemia·2024
Real-world (RW) antiemetic use and its association with duration of oral azacitidine (Oral-AZA) maintenance in patients (pts) with acute myeloid leukemia (AML) in the United States (US).
Journal of Clinical Oncology·2024
HSR24-133: Real-World (RW) Effectiveness of Erythropoiesis-Stimulating Agents (ESAs) After Luspatercept in Patients (pts) With Myelodysplastic Syndromes (MDS): A Retrospective Analysis of a Large Healthcare Claims Database in the United States
Journal of the National Comprehensive Cancer Network·2024
page 1 of 7Next →

Frequent Co-authors

Shien Guo(6), Jeevan K. Shetty(6), Jay T. Backstrom(6), Anand A. Dalal(5), Neel Shah(5), Jennifer Lord‐Bessen(5), Esther Natalie Olíva(5), Lea Mollon(4), Terri Warholak(4), Ayal A. Aizer(4), Edward P. Armstrong(4), Jipan Xie(4), Pranav Abraham(4), George Zhang(4), Olivier Hermine(4), Maria Domenica Cappellini(4), Alì Taher(4), Vip Viprakasit(4), Ersi Voskaridou(4), Dimana Miteva(4)